AlphAIAlphAI — Financial news for AI agents
fool.comAUG 262 min read$IRIX

IRIDEX (IRIX) Q2 2026 Earnings Call Transcript

IRIDEX (IRIX) reported Q2 2026 revenue of $12.6M, down 7% YoY, with Cyclo G6 product revenue up 19% but retina revenue down. Net loss was $1.3M. Management maintained full-year revenue guidance of $51M-$53M, excluding Middle East revenue, and expects low-double-digit glaucoma growth and low-single-digit retina growth in H2 2026.

Original reporting
fool.com
Published Aug 26, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IRIDEX (IRIX) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$IRIXNeutralMed
01

Why it matters

The earnings release provides fresh guidance and cash flow data, informing short‑term trading decisions.

02

Market read

First‑hand earnings data for a micro‑cap ophthalmic device company; relevant for sector‑specific traders.

03

What to watch

Potential upcoming MDR approval for PASCAL platform in 2027 may unlock future upside.

Relevance 6/10Novelty 7/10Timing: after‑hours release

Background

IRIDEX reported Q2 2026 results, highlighting mixed performance across product lines and ongoing operational transitions.

Company-level read

Ticker impact

$IRIXNeutralMedium confidence
Context

Q2 2026 earnings released with revenue down 7% YoY, net loss of $1.3M and full-year guidance unchanged.

Expected impact

Potential modest dip on earnings miss, but support near current levels due to cash flow positivity.

Evidence & confidence

Revenue decline and loss signal weakness, yet cash generation and unchanged guidance reduce risk of a sharp sell‑off.

Market effects

Sector

Glaucoma and retina device makers may see similar pressure from international regulatory transitions.

Regional

Middle East disruptions could affect other med‑tech firms with exposure in that region.

Global

Limited to ophthalmic device niche; broader market impact minimal.

Counterpoint

What could challenge this read

Despite revenue decline, the cash flow turn‑around and inventory build‑up could support a rebound.

Key entities

  • Executive
    Patrick Mercer

    CEO of IRIDEX, provided forward‑looking statements.

  • Executive
    Romeo R. Dizon

    CFO of IRIDEX, presented financial details.

Read at source← All news

Related articles

AUG 19
$IRIXMed

IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company

IRIDEX Corp (IRIX) reported Q2 2026 earnings, highlighting a 35% surge in Cyclo-G6 probe sales. CEO Patrick Mercer expects low single-digit retina growth for the year, driven by regulatory approvals and promotions, despite headwinds in the Middle East and China. The company placed fewer Cyclo-G6 systems due to regulatory delays but anticipates higher numbers in Q4. Glaucoma growth was broad-based, with strong US and international performance. Revenue decline was attributed to retina business and

yahoo.com2 min
AUG 18
$IRIXMed

IRIDEX CORP (IRIX): Results of Operations and Financial Condition

IRIDEX CORP (IRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for

SEC EDGAR 8-K6 min
SEP 20
$GEVMed

GE Vernova’s (GEV) $200 Billion Backlog is Coming Sooner than Expected

GE Vernova (GEV) CEO Scott Strazik expects the company's backlog to reach $200 billion in early 2027, earlier than anticipated. The company's Q2 2026 backlog was $176 billion, up 37% YoY, with revenue growing 22% YoY to $11.1 billion. GEV raised its 2026 revenue forecast to $45.5 billion-$46.5 billion. However, the company faces risks from AI bubble concerns and weakness in its Wind business.

insidermonkey.com3 min
SEP 20
$PLDMed

Prologis Sees Leasing Surge, Data Centers Fuel Growth Outlook

Prologis (PLD) reports a surge in leasing, with data centers driving growth. The company has secured 1.6 GW of power capacity and completed $2B in data center starts. U.S. logistics net absorption is 66M sq ft in Q2, with a 17% lease mark-to-market. Strong markets include Sun Belt, Texas, and Southern California. PLD expects e-commerce to reach 28-30% of U.S. retail sales by 2030.

finance.yahoo.com3 min
SEP 20
$RDDTMedAI 8/10

What Happens To Reddit Stock If Search Keeps Sending Fewer People?

Reddit (RDDT) stock is down 43% over the past year, trading near $153. Q2 2026 revenue grew 61% to $805 million, with an operating margin of 28.2%. Growth is driven by higher ad revenue per user, but search referrals are volatile. Management expects Q3 2026 revenue growth to slow to 47-49%. The company aims to improve user retention and become a destination site.

yahoo.com2 min
SEP 20
$ECOMed

Louis Navellier's stock scoring system spots 3 oil tanker stocks

Oil tanker companies Okeanis Eco Tankers (ECO), International Seaways (INSW), and DHT Holdings (DHT) report strong earnings due to higher shipping rates. ECO's Q2 revenue rose 239.6% YoY to $318.9M, INSW's revenue increased 138.8% YoY to $467.29M, and DHT's revenue grew 122.7% YoY to $284.8M. Analysts expect continued earnings growth for these companies.

yahoo.com3 min